Your browser doesn't support javascript.
loading
How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?
Salisbury-Afshar, Elizabeth; Livingston, Catherine J; Bluthenthal, Ricky N.
Affiliation
  • Salisbury-Afshar E; Addiction medicine, family medicine, and preventive medicine physician at the University of Wisconsin-Madison School of Medicine and Public Health.
  • Livingston CJ; Family physician and preventive medicine physician who serves as the medical director at Health Share of Oregon in Portland.
  • Bluthenthal RN; Distinguished professor in the Department of Population and Public Health Sciences at the University of Southern California in Los Angeles.
AMA J Ethics ; 26(7): E562-571, 2024 Jul 01.
Article in En | MEDLINE | ID: mdl-38958425
ABSTRACT
Practices and interventions that aim to slow progression or reduce negative consequences of substance use are harm reduction strategies. Often described as a form of tertiary prevention, harm reduction is key to caring well for people who use drugs. Evidence-based harm reduction interventions include naloxone and syringe service programs. Improving equitable outcomes for those with opioid use disorder (OUD) requires access to the continuum of evidence-based OUD care, including harm reduction interventions, as well as dismantling policies that undermine mental health and substance use disorder treatment continuity, housing stability, and education and employment opportunities.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Harm Reduction / Naloxone / Opioid-Related Disorders Limits: Humans Language: En Journal: AMA J Ethics Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Harm Reduction / Naloxone / Opioid-Related Disorders Limits: Humans Language: En Journal: AMA J Ethics Year: 2024 Document type: Article
...